Literature DB >> 10959222

Experience with testosterone replacement in the elderly.

J L Tenover1.   

Abstract

To date, most of the studies of androgen replacement have been done with healthy older men (age > or = 55 years), and almost no data are available for frail elderly individuals. Treatment effects that make a relatively small difference in younger, more robust individuals may have a greater effect on the elderly, whose improvement in functioning and level of activity may be more dramatic. However, the frail elderly individual is also more vulnerable to adverse effects from treatment, and these potential risks and benefits must be weighed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959222

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

Review 1.  Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression.

Authors:  L Zakaria; A G Anastasiadis; R Shabsigh
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 2.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Intramuscular Anabolic Signaling and Endocrine Response Following Resistance Exercise: Implications for Muscle Hypertrophy.

Authors:  Adam M Gonzalez; Jay R Hoffman; Jeffrey R Stout; David H Fukuda; Darryn S Willoughby
Journal:  Sports Med       Date:  2016-05       Impact factor: 11.136

4.  Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

5.  Androgen replacement therapy in the aging male.

Authors:  Jeremy B Myers; Randall B Meacham
Journal:  Rev Urol       Date:  2003

6.  Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis.

Authors:  Jasna Aleksova; Alexander J Rodriguez; Robert McLachlan; Peter Kerr; Frances Milat; Peter R Ebeling
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

7.  Myocytic androgen receptor controls the strength but not the mass of limb muscles.

Authors:  Céline Chambon; Delphine Duteil; Alban Vignaud; Arnaud Ferry; Nadia Messaddeq; Rocco Malivindi; Shigeaki Kato; Pierre Chambon; Daniel Metzger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 8.  Epigenetic drugs in the treatment of skeletal muscle atrophy.

Authors:  Valentina Guasconi; Pier Lorenzo Puri
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-05       Impact factor: 4.294

Review 9.  Androgen deficiency in the aging male: when to evaluate and when to treat.

Authors:  W E Nolten
Journal:  Curr Urol Rep       Date:  2000-12       Impact factor: 2.862

Review 10.  Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications.

Authors:  Mark W Pataky; William F Young; K Sreekumaran Nair
Journal:  Mayo Clin Proc       Date:  2021-03       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.